We established PKC-ι and PKC-ζ as oncogenes and identified as a prospective therapeutic target for melanoma and prostate carcinoma based on the aPKC specific inhibitors applications in recent times [19,20,35–38]. Here, PRKCA is linked to prostate carcinoma.